Skip to main content

Table 3 Summary of the major characteristic molecular features of GCB-DLBCL-NOS

From: Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review

Genetic Aberration: Gain of function

Genetic Aberration: Loss of function

Pathways: Upregulated/Gain

Pathways: Inhibited/Loss

Study

BCL2 (Tx/Ampl/Methyl)

 

BCL2

Pro-apoptotic signaling

[75, 362, 365]

EZH2 (Mut)

 

EZH, BCL2, BCL6

BLIMP1, CREBBP; EP300

[16, 17, 77–79]

BCL6 (Tx/Ampl/Methyl)

 

BCL6

BLIMP1, CREBBP; EP300

[87, 93, 148, 386, 612]

MEF2B/(MEF2C) (Mut)

 

BCL6

BLIMP1, CREBBP; EP300

[16, 17, 28]

MDM2 (Ampl)

TP53 (Del/Mut), TP73 (Del)

 

TP53 and TP73Pro-apoptotic signaling

[16, 17, 155, 613, 614]

c-MYC (Tx/Ampl/Methyl)

 

c-MYC, miR-17-92, BCR, PI3K/AKT/mTORC1

ISGs/IFITs, PTEN

[80, 81, 87]

miR-17-92

 

BCR, PI3K/AKT/mTORC1

ISGs/IFITs, PTEN

[13, 80, 81]

 

P2RY8 (Mut)

PI3K/AKT/mTORC1

(Mut)

[15–17, 84]

 

S1PR2 (Mut)

PI3K/AKT/mTORC1

(Mut)

[15–17, 84]

 

GNA13 (Mut)

PI3K/AKT/mTORC1

Gα13

[15–17, 84]

 

ARHGEF1 (Del/Mut)

PI3K/AKT/mTORC1

ARHGEF1

[15–17, 84]

 

PTEN (Del/Methyl/miR)

PI3K/AKT/mTORC1

PTEN

[13, 82, 83, 593]

 

B2M (Del/Mut)

 

B2M, HLA-I complex

[16, 17, 615, 616]

 

CD58 (Del/Mut)

 

CD58, HLA-I complex

[16, 17, 615, 616]

 

MLL2, MLL3 (Mut)

BCL6

MLL2/3, CREBBP; EP300

[12, 16, 17, 20]

 

CREBBP; EP300 (Del/Mut)

BCL6, HSP90,

CREBBP; EP300, BLIMP1, TP53

[16, 17, 19, 386, 388]

 

TNFRSF14 (Mut)

 

HVEM/FAS

[16, 17, 617]

 

FAS (Mut)

 

FAS/ Pro-apoptotic signaling

[16, 618]

 

TRAF3 (Del/Mut)

Non-canonical NF-κB signaling (p52/RELB),

??

[26, 27]

??

??

STAT1

 

[470]

  1. Overlapping molecular features of GCB- and ABC-DLBCL are marked as bold italic. Overlapping molecular features of PMLBCL, GCB-DLBCL and ABC-DLBCL are marked as bold. Normal letters refer to genetic aberrations that contribute to DLBCL pathogenesis, regardless of subtype.
  2. DLBCL diffuse large B cell lymphoma, ABC activated B cell-like, GCB germinal center B cell-like, PMLBCL primary mediastinal (thymic) large B-cell lymphomas, Del deleted/deletions, Mut mutated/mutations, Ampl amplified/amplification, Tx translocations, BCL2 B-cell lymphoma protein 2, BCL6 B-cell lymphoma protein 6, CREBBP CREB-binding protein, EP300 E1A-binding protein p300, EZH2 enhancer of zeste homologue 2, NF-κB nuclear factor- kappa B, PRDM1/BLIMP1 B-lymphocyte-induced maturation protein 1, TNFAIP3 tumor necrosis factor, alpha-induced protein 3, TRAF TNF-receptor-associated factor, MLL myeloid/lymphoid or mixed-lineage leukemia, TNFRSF14 tumor necrosis factor receptor superfamily, member 14, MDM2 murine double minute E3 ubiquitin protein ligase 2, STAT signal transducer and activator of transcription, P2RY8 purinergic receptor P2Y, G-protein coupled 8, S1PR2 sphingosine-1-phosphate receptor 2, MEF2B myocyte enhancer factor 2B, PTEN phosphatase and tensin homolog, FAS TNF receptor superfamily, member 6, HLA human leukocyte antigens, ISGs/IFITs interferon stimulated genes/interferon inducible transcription factors
Back to article page

Molecular Cancer

ISSN: 1476-4598